Sanofi SA (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 182   

Articles published

SNY 38.98 +0.57 (1.48%)
price chart
Sanofi SA (ADR) Chief Strategy Officer Resigns; Company Facing Another Turmoil ...
Sanofi SA (ADR) (NYSE:SNY), the French pharmaceutical giant, is facing another turmoil as its chief strategy officer, David-Alexandre Gros, has resigned only six months after the company's famous chief executive officer, Chris Viehbacher, was ousted by ...
Sanofi: Sanofi Pasteur to Fund Human Vaccines Project
Sanofi SA (ADR) (NSYE:SNY) vaccine division, Sanofi Pasteur, has finalized a deal with the Human Vaccines Project Inc. to partially provide funds for research.
Sanofi SA (ADR) And Regeneron Pharmaceuticals Inc Down With Praluent's Limited ...
Sanofi SA (NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) have received recommendation of approval for Praluent, their new drug.
How Big of an Impact Could Praluent Have on Regeneron Pharmaceuticals Inc.?  Motley Fool
Amgen, Inc. (NASDAQ:AMGN) Questioned By FDA Staff On Cholesterol Drug Benefits  USMarketsDaily (blog)
Regeneron Pharmaceuticals and Sanofi: FDA Accepts Sarilumab for BLA
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi SA (ADR) (NYSE:SNY) today announced that sarilumab had been accepted by the US Food and Drug Administration (FDA) for a Biologics License Application (BLA).
Sanofi SA (ADR) (SNY) Upgraded To Outperform By Leerink Partners
Sanofi SA (ADR) (NYSE:SNY) stock was upgraded from a Market Perform rating to an Outperform rating by analysts at Leerink Swann & Company in a research report issued to clients on Tuesday.
Leerink Swann & Company promoted Sanofi SA (ADR) (NYSE:SNY) to an Outplay  Stocks.org
Driven By Amgen, Inc. And Sanofi SA (ADR), US Drug Price War May Shift From ...
As per research presented at the annual meeting of the American College of Cardiology in March and conducted separately by Amgen, Inc. (NASDAQ:AMGN), and Sanofi SA (ADR) (NYSE:SNY) along with its development partner Regeneron Pharmaceuticals ...
Bristol-Myers Squibb Co, Sanofi SA (ADR), and Novartis AG (ADR) Lead 2015 ...
Bristol-Myers Squibb Co (NYSE:BMY), Sanofi SA (ADR)(NYSE:SNY), and Novartis AG's (ADR)(NYSE:NVS) will be 2015's most valuable new drug launches, says a report published on Monday.
Sanofi SA (ADR) Reports Positive Cardiovascular Safety Results For Diabetes ...
Sanofi SA (ADR) (NYSE:SNY) announced Thursday positive results for its diabetes drug Lyxumia from a Phase III study evaluating the cardiovascular risks of the said drug.
Sanofi Stock Update: Mergers, Licensure Agreements To Boost Company Revenue in ...
Sanofi ADR (NYSE:SNY) shares closed down 1.68% on December 31, 2015. The stock's beta value is 1.00. The company has a total market capitalization of $112.90 billion, with 1.31 billion outstanding shares.
VBI Vaccines Inc. (VBIV) Shares Soar After Partnership With Sanofi SA (ADR)
VBI Vaccines Inc. (NASDAQ:VBIV) jumped more than 20% in after-hours trade on Monday, following an announcement that the vaccines division of Sanofi SA (ADR) (NYSE:SNY), Sanofi Pasteur, will apply VBI's LPV™ (Lipid Particle Vaccine) formulation ...